Lumos Diagnostics Hits 250-Patient Mark Unlocking US$670K BARDA Payment
Lumos Diagnostics hits 250-patient enrolment milestone in BARDA-funded FebriDx paediatric study
Lumos Diagnostics Holdings Ltd (ASX: LDX) has completed Milestone #7 in its BARDA-funded FebriDx paediatric clinical study, confirming the enrolment of 250 patients and triggering a milestone payment of US$670,000. The achievement brings total BARDA milestone payments received to US$2,590,000, with the program maintaining steady progress toward a potential FDA label expansion covering children aged 2 to 12 years.
The non-dilutive nature of the BARDA funding structure is a notable positive for LDX shareholders. Each milestone completion delivers a cash payment without equity dilution, partially offsetting the costs of running the clinical programme as it advances.
Doug Ward, CEO and Managing Director
“The paediatric study continues to progress, and we look forward to the day that we can support clinicians in accurately assessing acute respiratory infections in younger children.”
When big ASX news breaks, our subscribers know first
What the BARDA milestone structure means for investors
A 12-milestone roadmap with defined triggers
The BARDA agreement comprises 12 milestone events, spanning the full lifecycle from clinical trial set-up through to FDA regulatory outcomes. Each event is tied to a defined cash payment rather than share issuance, meaning shareholders are not diluted as the programme progresses.
The milestone pathway covers four broad stages:
- Clinical trial set-up (early milestones)
- Patient recruitment (current stage — Milestone #7 now achieved)
- FDA submission (upcoming)
- FDA 510(k) clearance and CLIA-waiver categorisation for children aged 2–12 (final goal)
With 7 of 12 milestones now completed and US$2,590,000 received to date, the remaining US$3,608,459 in potential payments sits ahead of Lumos, subject to the programme’s continued progression. If all 12 milestones are achieved, total BARDA funding under the agreement will reach US$6,198,459.
The age expansion opportunity
A successful paediatric study outcome would broaden FebriDx’s approved US use from its current 12–64 year age range to 2–64 years, adding the younger paediatric cohort to an already cleared product.
The existing adult clearance, granted by the US FDA on 27 March 2026 (510(k) clearance with CLIA waiver for patients aged 12–64 years), provides recent regulatory context demonstrating the product’s established pathway. The paediatric study builds on that foundation, targeting the 2–12 year age group as the next addressable expansion.
Understanding FebriDx and why paediatric diagnostics matter
FebriDx is a rapid point-of-care test that delivers results in 10 minutes, helping clinicians differentiate bacterial from non-bacterial acute respiratory infections. This distinction matters because bacterial infections may warrant antibiotic treatment, while non-bacterial (typically viral) infections generally do not. Accurate differentiation supports antibiotic stewardship, the clinical practice of reducing unnecessary antibiotic prescribing to limit resistance.
The paediatric study is being conducted in CLIA-waived settings, which are broadly accessible healthcare locations, including primary care physician offices, urgent care clinics, retail health and pharmacy clinics, and community health centres. This accessibility is central to the commercial case.
The 27 March 2026 FDA clearance for adults expanded FebriDx’s US total addressable market 15-fold to over US$1.0 billion per annum, providing access to over 300,000 CLIA-waived locations and covering approximately 80 million acute respiratory consultations per year. A successful paediatric clearance would add the 2–12 age cohort to this already sizable commercial footprint, representing a further layer of market access once achieved.
The table below summarises the known milestone structure and payment progress under the BARDA agreement:
| Milestone Stage | Description | Status | Payment (US$) | Cumulative Received (US$) |
|---|---|---|---|---|
| Clinical trial set-up | Early programme establishment milestones | Completed | TBD | Part of US$1,920,000 prior to Milestone #7 |
| Patient recruitment (partial) | Milestones tied to interim enrolment targets | Completed | TBD | Part of US$1,920,000 prior to Milestone #7 |
| Patient recruitment — Milestone #7 | 250 patients enrolled | Completed (current) | US$670,000 | US$2,590,000 |
| Continued enrolment | Remaining patient recruitment milestones | Pending | TBD | TBD |
| FDA submission | Formal submission following study completion | Pending | TBD | TBD |
| FDA 510(k) clearance + CLIA waiver | Regulatory approval for children aged 2–12 years | Pending | TBD | TBD (up to US$6,198,459 total) |
Individual payment amounts per milestone (other than Milestone #7) have not been disclosed in the announcement. TBD entries reflect undisclosed figures, not omissions.
The next major ASX story will hit our subscribers first
What comes next for the FebriDx paediatric programme
With Milestone #7 now complete, the study is expected to run for approximately 12 months from its commencement date of 22 October 2025, implying a study completion period around October 2026. Following enrolment completion, the company anticipates preparing a formal FDA submission, subject to the data meeting the required statistical endpoints.
The remaining milestones include FDA submission and the FDA granting of 510(k) clearance and CLIA-waiver categorisation for children aged 2–12 years. These represent the programme’s most commercially significant triggers. Lumos has confirmed it will continue providing updates as further milestones are achieved.
For investors tracking near-term catalysts, the next milestone trigger as enrolment advances toward study completion represents the immediate watchpoint.
Don’t Miss the Next Healthcare Milestone Before the Market Moves
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to ensure the next major update lands with you first.